FDA rolls out guidance for seamless cancer trials

FDA released draft guidance Friday outlining how companies can use seamless trial designs to consolidate the traditional three-phase approach into one first-in-human study to expedite development of cancer drugs and biologics.

Seamless trials use a single protocol that runs continuously and is amended to expand cohorts and/or add new ones until there is

Read the full 522 word article

User Sign In